Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Wednesday, April 16, 2014
Aesica, the global pharmaceutical contract development and manufacturing organisation (CDMO), has led a consortium, also comprising Charnwood Technical Consulting, CatScI and Biocatalysts, which has successfully won a Technology Strategy Board grant...
read more
Aesica Pharmaceuticals, a global pharmaceutical contract development and manufacturing organization (CDMO), provides a novel, modular based solution that provides pharmaceutical customers with a highly flexible, efficient and reliable technological ...
read more
Aesica, the global contract manufacturing organisation (CMO), announces a partnership with the University of Nottingham for the commercial development of alternative methods in amide bond synthesis. This latest partnership is already the Aesica ...
read more
Wednesday, February 22, 2012
Global pharmaceutical manufacturer, Aesica, experienced significant growth in 2011, doubling both its turnover and its workforce and forming a number of long-term strategic partnerships with customers such as UCB and Noramco.
read more
Aesica has recruited a Technical Director to create global Lead Technical Centres for API development, drug product development and technology innovation.
read more
Tuesday, February 03, 2015
Aesica, the global pharmaceutical contract development and manufacturing organisation (CDMO), a division of Consort Medical plc, today announces it has received continuing FDA approvals for both its bulk manufacturing and packaging operations in ...
read more
Aesica, the global pharmaceutical contract development and manufacturing organisation (CDMO), has today announced that its High Capacity Manufacturing Facility has been successfully validated for commercial production. $45m (USD) has been invested at...
read more
Aesica, the global pharmaceutical contract development and manufacturing organisation (CDMO), has today announced it has successfully introduced serialisation services and initiated commercial production of two anti-allergy product lines for the ...
read more
Wednesday, September 23, 2015
Aesica, a global pharmaceutical contract development and manufacturing organization (CDMO), is pleased to announce its involvement in a renewable green initiative involving its UK, Cramlington site.
read more
Wednesday, October 31, 2012
Aesica, the global contract manufacturing organisation (CMO), announces that it has won the European Outsourcing award for ‘best acquisition’ following the successful acquisition and integration of three different UCB sites – at Monheim and Zwickau ...
read more
Aesica, the global contract development and manufacturing organisation (CDMO), is pleased to announce the 20th anniversary of its site located at Zwickau in Germany. The facility possesses multiple solid oral dosage form technologies and service ...
read more
Wednesday, November 25, 2020
Aeterna Zentaris has entered into an amendment of its existing License Agreement with NNBL related to the development and commercialization of macimorelin.
read more
Thursday, December 17, 2020
Aeterna Zentaris has entered into a licensing agreement with Consilient Health for the commercialization in Europe and the United Kingdom of macimorelin.
read more
Tuesday, January 26, 2016
Aeterna Zentaris Inc. has filed an international patent application as well as national patent applications in selected countries including the US, China, Taiwan, Japan and India. These applications seek to protect the novel method of manufacturing ...
read more
Aeterna Zentaris Inc. has executed a definitive agreement with Ergomed to manage the new, confirmatory Phase 3 clinical study to demonstrate the efficacy of Macrilen™ (macimorelin), a novel orally-active ghrelin agonist for use in evaluating adult ...
read more